이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medical Developments International 관리

관리 기준 확인 2/4

Medical Developments International's CEO는 Brent MacGregor, Nov2020 에 임명되었습니다 의 임기는 3.58 년입니다. 총 연간 보상은 A$ 1.94M, 29.7% 로 구성됩니다. 29.7% 급여 및 70.3% 보너스(회사 주식 및 옵션 포함). 는 A$ 9.88K 가치에 해당하는 회사 주식의 0.029% 직접 소유합니다. 9.88K. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 3.5 년입니다.

주요 정보

Brent MacGregor

최고 경영자

AU$6.2m

총 보상

CEO 급여 비율	9.8%
CEO 임기	3.8yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Brent MacGregor 의 보수는 Medical Developments International 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$6m	AU$602k	-AU$41m
Mar 31 2024	n/a	n/a	-AU$30m
Dec 31 2023	n/a	n/a	-AU$19m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$2m	AU$576k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$2m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$2m	AU$547k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$16m
Dec 31 2021	n/a	n/a	-AU$19m
Sep 30 2021	n/a	n/a	-AU$16m
Jun 30 2021	AU$1m	AU$351k	-AU$13m

보상 대 시장: Brent 의 총 보상 ($USD 1.30M )은 Australian 시장( $USD 298.77K ).

보상과 수익: 회사가 수익성이 없는 동안 Brent 의 보상이 증가했습니다.

CEO

Brent MacGregor (60 yo)

3.8yrs

테뉴어

AU$6,166,500

보상

Mr. Brent MacGregor serves as an Independent Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since Novemb...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brent MacGregor	Chief Executive Officer	3.8yrs	AU$6.17m	0.18% A$ 97.3k
Anita James	Chief Financial Officer	2.3yrs	AU$5.94m	0.049% A$ 27.1k
Matthew Cramer	Chief of Operations & Supply Chain	4.7yrs	데이터 없음	데이터 없음
Scott Courtney	Chief Scientific Officer	5.2yrs	데이터 없음	데이터 없음
Tara Eaton	General Counsel & Company Secretary	2.1yrs	데이터 없음	데이터 없음
Wai Chi	Head of Regulatory Affairs	5.8yrs	데이터 없음	데이터 없음
Wayne Pearce	Head of Production	4.2yrs	데이터 없음	데이터 없음
Stefaan Schatteman	Head of Europe	4.1yrs	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

경험이 풍부한 관리: MVP 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gordon Naylor	Non-Executive Chairman	3.9yrs	AU$95.00k	1.03% A$ 562.8k
Mary Sontrop	Non-Executive Director	3.5yrs	AU$60.00k	0.016% A$ 8.9k
Russell Basser	Non-Executive Director	less than a year	AU$50.00k	0.012% A$ 6.8k
Leon Hoare	Non-Executive Director	11yrs	AU$60.00k	0.049% A$ 26.7k
Richard Betts	Non-Executive Director	3.3yrs	AU$60.00k	0.018% A$ 10.1k
Christine Emmanuel-Donnelly	Non-Executive Director	4.3yrs	AU$60.00k	0.071% A$ 39.0k

3.7yrs

평균 재임 기간

경험이 풍부한 이사회: MVP 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Medical Developments International 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Recent updates

Medical Developments International Limited, Annual General Meeting, Oct 24, 2024

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$0.067 loss in FY 2023)

New minor risk - Shareholder dilution

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.

Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024

New minor risk - Profitability

Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024

Medical Developments International Limited, Annual General Meeting, Oct 27, 2023

Full year 2023 earnings released: AU$0.067 loss per share (vs AU$0.17 loss in FY 2022)

Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023

Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

New minor risk - Share price stability

First half 2023 earnings released: EPS: AU$0.032 (vs AU$0.10 loss in 1H 2022)

Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023

Medical Developments International Limited Discontinues China Clinical Trials

No independent directors

Medical Developments International Limited Announces Resignation of Max Johnston as Director, Effective 27 October 2022

Medical Developments International Limited, Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: AU$0.17 loss per share (vs AU$0.18 loss in FY 2021)

Medical Developments International Limited Provides Earnings Guidance for the Fiscal Year 2022 and Revenue Guidance for the Fiscal Year 2023

Medical Developments International Limited to Report Fiscal Year 2022 Results on Aug 26, 2022

Medical Developments International Limited Appoints Tara Eaton as General Counsel and Company Secretary, Effective August 8, 2022

No independent directors

Medical Developments International Limited Announces That US Food and Drug Administration Lifts Clinical Hold on Penthrox

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medical Developments International Limited to Report Q2, 2022 Results on Feb 24, 2022

Non-Executive Chairman recently bought AU$306k worth of stock

Non-Executive Chairman recently bought AU$1.0m worth of stock

Full year 2021 earnings released: AU$0.18 loss per share (vs AU$0.006 profit in FY 2020)

Medical Developments International Limited Provides Sales Guidance for the Fiscal Year 2022

Medical Developments International Limited Announces Earnings Guidance for the Year Ended June 30, 2021

Non-Executive Chairman recently bought AU$534k worth of stock

Medical Developments International Limited Appoints Mary Sontrop as Non-Executive Director

Revenue misses expectations

First half 2021 earnings released: AU$0.017 loss per share (vs AU$0.004 profit in 1H 2020)

New 90-day low: AU$6.05

New 90-day high: AU$7.13

Medical Developments International Limited Announces Executive Changes

New 90-day high: AU$6.59

Medical Developments International Limited Appoints Brent Macgregor as Chief Executive Officer, Effective November 1, 2020

Medical Developments International Limited Declares No Dividend for the Full Year Ended 30 June 2020

New 90-day low: AU$5.27

New 90-day low - AU$5.51

Full year earnings released

Medical Developments International Limited(ASX:MVP) dropped from S&P/ASX Emerging Companies Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간